TaiMed Biologics Inc. (TPEX: 4147)
Health Care · Biotechnology · TW
NT$63.10
-1.71% today · -21.1% 1Y
TaiMed Biologics Inc. (TPEX: 4147) operates in the Biotechnology industry within the Health Care sector. The company is valued at $541.38M and employs 799 people.
Over the last twelve months the share price has lost 21.1%, trading between 47.00 and 82.80.
Tweenvest scores TaiMed Biologics Inc. across four factors: quality 62/100, value 53/100. Its strongest factor is quality.
4147 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $541.38M
- Revenue (TTM)
- $19.47M
- P/E
- —
- EPS
- -0.51
- Dividend yield
- —
- Beta (5Y)
- -0.16
- 52-week high
- NT$82.80
- 52-week low
- NT$47.00
- Avg volume (3M)
- —
- Shares outstanding
- 273.20M
- Employees
- 799
- Next earnings
- —
About TaiMed Biologics Inc.
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.
- ISIN
- TW0004147004
- Founded
- 2007
- Listed since
- Jun 20, 2012
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.